Neogen (NASDAQ:NEOG) announced its quarterly earnings results on Thursday. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.23 by $0.09, Briefing.com reports. Neogen had a return on equity of 10.72% and a net margin of 13.47%. The company had revenue of $95.90 million for the quarter, compared to the consensus estimate of $97.93 million. During the same quarter last year, the company posted $0.27 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year.
Neogen (NASDAQ:NEOG) opened at $62.53 on Friday. The company has a market capitalization of $3,284.05, a P/E ratio of 62.22, a price-to-earnings-growth ratio of 3.95 and a beta of 1.42. Neogen has a twelve month low of $44.63 and a twelve month high of $65.30.
In other news, CFO Steven J. Quinlan sold 2,000 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $60.15, for a total value of $120,300.00. Following the sale, the chief financial officer now owns 15,470 shares in the company, valued at $930,520.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Edward Bradley sold 11,725 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $60.29, for a total transaction of $706,900.25. Following the completion of the sale, the vice president now owns 21,412 shares in the company, valued at approximately $1,290,929.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,382 shares of company stock worth $3,939,913. 4.20% of the stock is currently owned by corporate insiders.
Several brokerages have commented on NEOG. BidaskClub downgraded Neogen from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Stephens reiterated a “hold” rating and set a $62.00 price target on shares of Neogen in a report on Wednesday, January 10th. Zacks Investment Research downgraded Neogen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 15th. Craig Hallum increased their price target on Neogen from $46.50 to $60.00 and gave the company a “hold” rating in a report on Thursday, December 7th. Finally, Roth Capital began coverage on Neogen in a report on Tuesday, December 5th. They set a “neutral” rating and a $61.50 price target on the stock. Five equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. Neogen has an average rating of “Hold” and a consensus target price of $63.25.
ILLEGAL ACTIVITY WARNING: “Neogen (NEOG) Issues Quarterly Earnings Results” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2018/03/22/neogen-neog-announces-quarterly-earnings-results.html.
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.